Ildong Pharmaceutical Co., Ltd. (KRX:249420)
South Korea flag South Korea · Delayed Price · Currency is KRW
14,800
+440 (3.06%)
Last updated: Aug 28, 2026, 2:28 PM KST

Ildong Pharmaceutical Cash Flow Statement

Millions KRW. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
43,60927,664-4,576-78,928-141,585-99,705
Depreciation & Amortization
22,06922,57625,93528,31929,54529,311
Loss (Gain) From Sale of Assets
908.092,1464,908-1,133282.22101.53
Asset Writedown & Restructuring Costs
-2,5369,8573,49219,004550.27
Loss (Gain) From Sale of Investments
-9,459-7,643-1,955-439.72-2,325862.82
Loss (Gain) on Equity Investments
-761.36-283.69273.490.360.541.67
Stock-Based Compensation
33.57215.08129.79-5.7318.0916.55
Provision & Write-off of Bad Debts
-1,923243.8303.04-574.49-85.1-1,142
Other Operating Activities
1,245-1,0371,44924,14056,02060,178
Change in Accounts Receivable
-2,066-2,6543,634-2,089-1,407-1,857
Change in Inventory
1,053-13,506-2,50813,852-15,5326,617
Change in Accounts Payable
-3,033229.27-2,9734,2357,9362,339
Change in Other Net Operating Assets
-16,232-11,537-6,185-27,484-5,412-8,639
Operating Cash Flow
35,44318,95128,293-36,615-53,541-11,366
Operating Cash Flow Growth
118.34%-33.02%----

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-13,013-13,647-10,679-13,201-11,873-14,626
Sale of Property, Plant & Equipment
146.31161.7129,336307.0167.538.14
Divestitures
184.32184.3279.74--4,142
Sale (Purchase) of Intangibles
-1,794-3,637-1,150-1,968-6,401-4,876
Investment in Securities
618.956,64912,759-1,601-7,401-26,180
Other Investing Activities
-2,585-913.62-344.221,025-842.621,133
Investing Cash Flow
-4,197-2,27918,458-20,360-26,435-43,368

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Short-Term Debt Issued
-14,71515,03084,50023,000141,600
Long-Term Debt Issued
--50,00029,25017,00099,400
Total Debt Issued
15,42314,71565,030113,75040,000241,000
Short-Term Debt Repaid
--21,920-87,519-48,700-20,000-133,600
Long-Term Debt Repaid
--26,369-3,573-4,850-23,118-10,723
Total Debt Repaid
-60,113-48,289-91,092-53,550-43,118-144,323
Net Debt Issued (Repaid)
-44,690-33,575-26,06260,200-3,11896,677
Issuance of Common Stock
---124.83-1,745
Repurchase of Common Stock
-1.04-0.87-0.17-1,942--
Dividends Paid
-6,302-60.16-76.8-160-120-
Other Financing Activities
9,5479,547-366.08-70.4-49.31-0
Financing Cash Flow
-36,445-24,088-27,85458,152-3,287104,316

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Foreign Exchange Rate Adjustments
132.96-4.84112.18-64.19-177.2440.44
Net Cash Flow
-5,067-7,42219,0091,112-83,44050,022

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
22,4305,30417,614-49,817-65,413-25,992
Free Cash Flow Growth
238.47%-69.89%----
Free Cash Flow Margin
3.85%0.94%2.86%-8.29%-10.26%-4.64%
Free Cash Flow Per Share
688.80172.61630.60-1843.01-2483.08-1092.76
Levered Free Cash Flow
10,272-20,183-6,7075,487-159,418101,154
Unlevered Free Cash Flow
15,476-12,5743,25414,690-153,300107,752

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash Interest Paid
7,2837,99513,53410,4125,6434,041
Cash Income Tax Paid
1,3411,902560.83724.882,524-290.57
Change in Working Capital
-20,279-27,467-8,032-11,485-14,416-1,540